



Suggested Reading

- Armoundas, A. A., Narayan, S. M., Arnett, D. K., et al. (2024). Use of artificial intelligence in improving outcomes in heart disease: a scientific statement from the American Heart Association. *Circulation*, 149(14), e1028–e1050.
<https://doi.org/10.1161/CIR.0000000000001201>
- Bhattacharya, R., Uddin, M. M., Patel, et al. (2025). Importance of clinical, laboratory, and genetic risk factors for incident coronary artery disease. *Circulation: Genomic and Precision Medicine*, 18(4), e004937. <https://doi.org/10.1161/CIRCGEN.124.004937>
- Chekouo, T., & Safo, S. E. (2020). Bayesian integrative analysis and prediction with application to atherosclerosis cardiovascular disease. *arXiv*.
<https://arxiv.org/abs/2005.11586>
- Clearly. (2023, November 11). Clearly, partners announce TRANSFORM trial to evaluate personalized heart disease care strategies at AHA 2023.
<https://www.jacc.org/doi/abs/10.1016/j.jacc.2024.05.003>
- Cohen, J. C., Boerwinkle, E., Mosley, et al. (2006). Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *The New England Journal of Medicine*, 354(12), 1264–1272. <https://doi.org/10.1056/NEJMoa054013>
- Elias, P, Jain, S, Poterucha, T. et al. Artificial intelligence for cardiovascular care—part 1: advances: JACC review topic of the week. *JACC*. 2024 Jun, 83 (24) 2472–2486. <https://doi.org/10.1016/j.jacc.2024.03.400>
- Hageman, S. H. J., et al. (2024). Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European populations. *European Heart Journal*. (Advance online publication)
<https://doi.org/10.1093/eurheartj/ehad>
- Kathiresan, S. (2008). A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. *The New England Journal of Medicine*, 358(21), 2299–2300.
<https://doi.org/10.1056/NEJMc0707445>
- Khera, R., Oikonomou, E. K., Nadkarni, G. N., et al. (2024). Transforming cardiovascular care with artificial intelligence: From discovery to practice: JACC state-of-the-art review. *Journal of the American College of Cardiology*, 84(1), 97–114.
<https://doi.org/10.1016/j.jacc.2024.05.003>

- Klarin, D., & Natarajan, P. (2022). Clinical utility of polygenic risk scores for coronary artery disease. *Nature Reviews Cardiology*, 19(4), 291–301.
<https://doi.org/10.1038/s41569-021-00638-w>
- Linsel-Nitschke, P., et al. (2008). Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease: a mendelian randomisation study. *PLOS ONE*, 3(8), e2986.
<https://doi.org/10.1371/journal.pone.0002986>
- McDermott, M., et al. (2024). Rationale and design of the SCOT-HEART 2 Trial: CT angiography for the prevention of myocardial infarction. *Journal of the American College of Cardiology: Cardiovascular Imaging*, 17(9), 1101-1112.
<https://doi.org/10.1016/j.jcmg.2024.05.016>
- Mensah, G. A., Arnold, N., Prabhu, S. D., Ridker, P. M., Welty, F. K., et al. (2025). Inflammation and cardiovascular disease: 2025 ACC scientific statement. *Journal of the American College of Cardiology*. <https://doi.org/10.1016/j.jacc.2025.08.047>
- Newby, D. E., Adamson, P. D., Berry, et al. (2018). Coronary CT angiography and 5-year risk of myocardial infarction. *The New England Journal of Medicine*, 379(10), 924-933.
<https://doi.org/10.1056/NEJMoa180597>
- O’Sullivan, J. W., Raghavan, S., Marquez-Luna, C., et al. (2022). Polygenic risk scores for cardiovascular disease: A scientific statement from the American Heart Association. *Circulation*, 146(8), e93–e118. <https://doi.org/10.1161/CIR.0000000000001077>
- Williams, M. C., et al. (2025). Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(24\)02679-5](https://doi.org/10.1016/S0140-6736(24)02679-5)
- Zaman, S., Wasfy, J. H., Kapil, et al. (2025). The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma. *The Lancet*, 405(10486), 1264-1312. [https://doi.org/10.1016/S0140-6736\(25\)00055-8](https://doi.org/10.1016/S0140-6736(25)00055-8)